JAK2 mutation–positive polycythaemia vera associated with IgA vasculitis and nephrotic syndrome: a case report

References

• Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.
   PubMed Web of Science ®Google Scholar
• Rai A, Nast C, Adler S. Henoch-Schönlein purpura nephritis. J Am Soc Nephrol. 1999;10(12):2637–2644.
   Web of Science ®Google Scholar
• Hocever A, Rotar Z, Jurcic V, et al. Patient age, gender and extent of purpura may suggest short-term outcomes in adults with IgA vasculitis. Rheumatology (Oxford). 2015;54:1330–1332.
   Web of Science ®Google Scholar
• Tracy A, Subramanian A, Adderley NJ, et al. Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Schönlein purpura): a retrospective cohort study using routinely collected primary care data. Ann Rheum Dis. 2019;78(2):261–269.
   Web of Science ®Google Scholar
• Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. Blood. 2017;130(23):2475–2483.
   PubMed Web of Science ®Google Scholar
• Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376(22):2168–2181.
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling cuases polycythemia vera. Nature. 2005;434(7037):1144–1148.
   PubMed Web of Science ®Google Scholar
• Bazter E, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061.
   Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–806.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426–435.
   PubMed Web of Science ®Google Scholar
• Fujita K, Hatta K. Renal biopsy cases in myeloproliferative neoplasms (MPN). CEN Case Rep. 2013;2(2):215–221.
   Google Scholar
• Kasuno K, Ono T, Kamata T, et al. IgA nephropathy associated with polycythemia vera: accelerated course. Nephrol Dial Transplant. 1997;12(1):212–215.
   Web of Science ®Google Scholar
• Chung J, Park PG, Song KI. IgA nephropathy in a patient with polycythemia vera. Clinical manifestation of chronic renal failure and heavy proteinuria. Am J Nephrol. 2002;22(4):397–401.
   Web of Science ®Google Scholar
• Chen H, Zhang B, Li M, et al. Polycythemia vera associated with IgA nephropathy: a case report and literature review. Exp Ther Med. 2015;10(2):555–560.
   Web of Science ®Google Scholar
• Kanauchi M, Dohi K, Shiiki H, et al. Henoch-Schönlein purpura nephritis associated with polycythemia vera. Intern Med. 1994;33(1):36–40.
   Web of Science ®Google Scholar
• Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69(5):798–806.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2017.
   Google Scholar
• Hocever A, Tomsic M, Rotar Z. IgA vasculitis in adults: few certainties and many uncertainties. Ann Rheum Dis. 2019;0:1.
   Google Scholar
• Belman AL, Leicher CR, Moshe SL, et al. Neurologic menifestations of Schonlein- Henoch purpura: report of three cases and review of the literature. Pediatrics. 1985;75(4):687–692.
   PubMed Web of Science ®Google Scholar
• Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33.
   PubMed Web of Science ®Google Scholar
• Barbui T, Masciulli A, Marfisi MR, et al. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood. 2015;126(4):560–561.
   PubMed Web of Science ®Google Scholar
• Edelmann B, Gupta N, Schnoeder TM, et al. JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation. J Clin Invest. 2018;128(10):4359–4371.
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366(9501):1945–1953.
   PubMed Web of Science ®Google Scholar
• Shi D, Chan H, Yang X, et al. Risk factors associated with IgA vasculitis with nephritis (Henoch-Schonlein purpura nephritis) progressing to unfavorable outcomes: a meta-analysis. PLoS One. 2019;14(10):e0223218.
   Web of Science ®Google Scholar
• Audemard-Verger A, Pillebout E, Guillevin L, et al. IgA vasculitis (Henoch-Schönlein purpura) in adults: diagnostic and therapeutic aspects. Autoimmun Rev. 2015;14(7):579–585.
   PubMed Web of Science ®Google Scholar
• Watanabe R, Ishii T, Kobayashi H, et al. Prevalence of hepatitis B virus infection in patients with rheumatic diseases in Tohoku area: a retrospective multicenter survey. Tohoku J Exp Med. 2014;233(2):129–133.
   Web of Science ®Google Scholar
• Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25–36.
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, El Jammal T, Vuitton L, et al. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2019;18(11):102390.
   PubMed Web of Science ®Google Scholar
• Zhang H, Watanabe R, Berry GJ, et al. Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis. Circulation. 2018;137(18):1934–1948.
   PubMed Web of Science ®Google Scholar
• Koudoukpo C, Jachiet M, Zini M, et al. Urticarial vasculitis associated with essential thrombocythemia progressing to myelofibrosis. Ann Dermatol Venereol. 2014;141(12):773–776.
   Web of Science ®Google Scholar
• Beynon C, Huws G, Lawson T. Myeloproliferative disease: an unusual cause of Raynaud’s phenomenon and digital ischemia. Case Rep Med. 2016;2016:1–2.
   Google Scholar